| Preclinical development of CD38-targeted [89Zr] Zr-DFO-daratumumab for imaging multiple myeloma A Ghai, D Maji, N Cho, C Chanswangphuwana, M Rettig, D Shen, ... Journal of Nuclear Medicine 59 (2), 216-222, 2018 | 57 | 2018 |
| Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival D Hathi, C Chanswangphuwana, N Cho, F Fontana, D Maji, J Ritchey, ... Scientific reports 12 (1), 30, 2022 | 14 | 2022 |
| The feasibility of implementing targeted sedation in mechanically ventilated emergency department patients: the ED-SED pilot trial BM Fuller, BW Roberts, NM Mohr, B Faine, AM Drewry, BT Wessman, ... Critical care medicine 50 (8), 1224-1235, 2022 | 13 | 2022 |
| Preclinical development of near-infrared-labeled CD38-targeted daratumumab for optical imaging of CD38 in multiple myeloma N Cho, S Ko, M Shokeen Molecular imaging and biology 23, 186-195, 2021 | 11 | 2021 |
| Changing landscape of optical imaging in skeletal metastases N Cho, M Shokeen Journal of Bone Oncology 17, 100249, 2019 | 7 | 2019 |
| Spatial organization of superparamagnetic iron oxide nanoparticles in/on nano/microsized carriers modulates the magnetic resonance signal MK Lee, NE Clay, E Ko, CE Smith, L Chen, N Cho, HJ Sung, L DiPietro, ... Langmuir 34 (50), 15276-15282, 2018 | 7 | 2018 |
| Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma N Cho, S Ko, M Shokeen Oncotarget 12 (20), 2039, 2021 | 3 | 2021 |
| Development of a Near-Infrared Fluorescent Daratumumab-Based Drug Conjugate for Targeted Imaging and Therapy in Preclinical Multiple Myeloma N Cho Washington University in St. Louis, 2021 | | 2021 |
| Development of a near-infrared daratumumab-based contrast agent for preclinical imaging of CD38 expression in multiple myeloma N Cho, S Ko, M Shokeen Cancer Research 80 (16_Supplement), 1649-1649, 2020 | | 2020 |
Walter J AkersUniversity of Texas Southwestern Medical CenterVerified email at utsouthwestern.edu
